中国经济网北京12月5日讯 据同花顺iFinD数据显示，2025年前11月里，在共计970只（各份额分开 计算）普通股票型基金中，仅有29只基金收跌，而这其中，就有知名基金经理萧楠管理的易方达消费行 业股票。数据显示，该基金在今年前11月收益率下跌0.14%。 作为消费主题基金，其重仓股自然以消费板块为主，然而纵观年内前三个季度的季报看，前十大重 仓股中，白酒股无疑都占据较大仓位。今年三季报显示，其前十大重仓股为贵州茅台、山西汾酒、五粮 液、福耀玻璃、美的集团、古井贡酒、长城汽车、东鹏饮料、泸州老窖、赛轮轮胎，白酒股占据一半。 （责任编辑：刘畅 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com | 代码 名称 | 前11月复权单位 累计单位 规模 亿 | | --- | --- | | | 净值增长率% 净值元 元 | | 110022.0F 易方达消费行业股票 | -0.14 3.5660 169.4 ...

中国经济网北京12月5日讯 据同花顺iFinD数据显示，2025年前11月里，在共计970只（各份额分开计 算）普通股票型基金中，仅有29只基金收跌，而这其中，就有知名基金经理萧楠管理的易方达消费行业 股票。数据显示，该基金在今年前11月收益率下跌0.14%。 作为消费主题基金，其重仓股自然以消费板块为主，然而纵观年内前三个季度的季报看，前十大重仓股 中，白酒股无疑都占据较大仓位。今年三季报显示，其前十大重仓股为贵州茅台、山西汾酒、五粮液、 福耀玻璃、美的集团、古井贡酒、长城汽车、东鹏饮料、泸州老窖、赛轮轮胎，白酒股占据一半。 | 来源：同花顺 | | --- | (责任编辑：徐自立) 资料显示，易方达消费行业股票成立于2010年8月20日，截至2025年12月4日的累计收益率为254.2%， 截至今年三季度末的规模为169.49亿元。 ...

Core Insights - Zhihai Club achieved significant returns in the Chinese fund market from 2018 to 2020 through precise investments and advanced technology [1][9] - The club utilized smart risk control, big data analysis, and artificial intelligence to identify market opportunities [1][9] Investment Strategies and Outcomes - In 2018, despite global economic slowdowns and trade tensions, Zhihai Club invested in the "Huaxia Technology Innovation Mixed Fund," focusing on sectors like 5G and AI, which later saw substantial growth [3] - The "E Fund Consumer Industry Stock Fund" was also targeted, capitalizing on the resilience of the Chinese consumer market, leading to steady net value increases during the same period [5] - In 2019, the club invested in the "Southern Sci-Tech Board Selected Mixed Fund," benefiting from the active performance of Sci-Tech board companies, resulting in excellent returns [7] - The "Bosera Credit Bond Fund" was chosen for its stable performance amid economic pressures, providing consistent returns and reducing portfolio volatility [7] - In 2020, the club increased investments in healthcare and online economy-related funds, notably the "Guangfa Healthcare Stock Fund," which saw significant net value growth due to heightened health awareness during the pandemic [8] - The investment in the "China Securities Index White Wine Fund" also proved successful, as the white wine sector rebounded post-pandemic, leading to substantial profits for the club [8] Overall Performance - From 2018 to 2020, Zhihai Club's successful investments across multiple funds, including the Huaxia Technology Innovation Mixed Fund, E Fund Consumer Industry Stock Fund, Southern Sci-Tech Board Selected Mixed Fund, Bosera Credit Bond Fund, Guangfa Healthcare Stock Fund, and China Securities Index White Wine Fund, demonstrated its strong capabilities in financial investment [9]

Group 1 - Jianxin Fund plans to invest at least 180 million yuan in its equity public products, having already invested 173 million yuan from Q4 2024 to Q1 2025 [1] - Multiple Hong Kong Stock Connect ETFs have issued warnings about premium risks due to high trading activity during the market closure, with some ETFs experiencing daily turnover rates exceeding 900% [1] - QDII funds have significantly reduced their holdings in US stocks, reallocating to A-shares and Hong Kong stocks [1] Group 2 - Fund manager Ge Lan has reduced her stake in Xinlitai by 2.1673 million shares, as reported in the company's Q1 2025 report [2] - Fund manager Fu Pengbo has slightly increased his position in Furuide by 120,000 shares, according to the latest Q1 2025 report [2] - Fund manager Xiao Nan has increased the allocation to liquor stocks, viewing it as a high-yield bond with domestic demand upside [3] Group 3 - The market showed mixed performance with the Shanghai Composite Index up 0.25% and the Shenzhen Component down 0.36%, with a total trading volume of 1.09 trillion yuan [4] - Hong Kong innovative drug-related ETFs saw strong performance, with some rising by as much as 5.77% [4][5] - A report indicates that the pharmaceutical sector may attract market funds due to previous declines, with investment opportunities focusing on innovative and generic drugs, as well as medical devices and services [7] Group 4 - A new fund, the China Securities Index Free Cash Flow ETF, is set to launch, managed by Xu Rongman, with a performance benchmark based on the China Securities Index Free Cash Flow Index [8]